The Woodlands, TX, and St. Louis, MO, March 14, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement... The post Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s O...
